“Indian Companies Launch Generic Semaglutide After Patent”

Several major Indian pharmaceutical companies have launched generic versions of the drug Semaglutide following the expiration of the patent for the active ingredient. On March 21, Sun Pharmaceutical, Dr. Reddy’s Laboratories, Zydus Life Sciences, and Glenmark Pharmaceuticals announced their versions of the drug.

The original drug, produced by Danish pharmaceutical giant Novo Nordisk, is sold under the brand names Wegovy and Ozempic, and is widely used for diabetes management and weight loss. With the patent now expired in India, other companies can legally produce and sell cheaper versions of the medicine.

Before these recent launches, Natco Pharma and its partner Eris Lifesciences had already announced that their generic Semaglutide would be available from the first day of the patent expiry, March 20.

The entry of multiple generic manufacturers is expected to increase competition in the market and make the drug more affordable for patients. Industry analysts estimate that the market for Semaglutide in India could reach around $1 billion in the next few years, with more companies likely to join in and launch their versions.

This development is significant for patients with diabetes and obesity, as it provides more accessible treatment options. Experts say that generic drugs can dramatically reduce costs while maintaining the same effectiveness as branded medicines.

The launch of these generics also highlights the growth of India’s pharmaceutical sector, which continues to play a major role in supplying affordable medicines both domestically and globally.